British drugmaker AstraZeneca is working with regulators to investigate a lower dosage of its vaccine that performed better than a full dosage, a spokesman for the company said on Thursday, after its chief executive was quoted as saying an additional global trial was likely.
This report produced by Jillian Kitchener.
